Kondo N, Hirano F, Iritani S, Suzuki K, Miyazaki A, Temma T. Preclinical evaluation of 5F-αMe-3BPA for improving pharmacokinetics in Boron Neutron Capture Therapy. Pharmaceutics. 2026;18(5):604. DOI：10.3390/pharmaceutics18050604.
Kondo N, Hirano F, Kanai Y, Suzuki K, Miyazaki A, Temma T. A LAT1-selective PET tracer, 5-[¹⁸F]F-αMe-3BPA, as a companion to its structurally matched ¹⁰B analog in boron neutron capture therapy. Eur J Nucl Med Mol Imaging. 2026;53(4):2566-2577. DOI: 10.1007/s00259-025-07668-3.
■ 2025
Kondo N, Kato M, Oshima A, Hirano F, Miyazaki A, Temma T. Radioiodinated bicyclic RGD peptide derivatives for enhanced tumor accumulation. Pharmaceuticals (Basel). 2025;18(4):549. DOI: 10.3390/ph18040549.
Futatsugi M, Miyazaki A, Kanai Y, Kondo N, Temma T. Fluorine-18-labeled Positron Emission Tomography probe targeting activated p38alpha: design, synthesis, and in vivo evaluation in rodents. Pharmaceuticals (Basel). 2025;18(4):600. DOI: 10.3390/ph18040600.
Kondo N, Yonezawa M, Hirano F, Temma T. Comparison of Exendin-4 and Its single amino acid substitutions as parent peptides for GLP-1 receptor imaging probes. Molecules. 2025;30(5):1011. DOI:10.3390/molecules30051011.
Takada S, Du HH, Kondo N, Miyazaki A, Hara F, Horiyama S, Temma T, Hagimori M. A Long-Wavelength Fluorescent Probe for Efficient Dual-Color Imaging of Boronic-Acid-Containing Agents in Living Cells. Chemosensors. 2025;13(8). DOI:10.3390/chemosensors13080283.
Hara F, Mizuyama N, Fujino T, Takada S, Temma T, Saji H, Mukai T, Hagimori M. Development of a Pyrone-Fused Tricyclic Scaffold-based Ratiometric Fluorescent Probe for Al(3+) Detection. J Fluoresc. 2025;35(6):4559-68. DOI:10.1007/s10895-024-03864-w.
Imamichi S, Ito T, Tong Y, Gao Z, Arai Y, Fujimori H, Chen L, Sanada Y, Nakamura S, Murakami Y, Ishiai M, Suzuki M , Itami J, Igaki H, Masunaga S and Masutani M. Transcriptome analysis of human oral squamous cancer SAS cells as an early response after boron neutron capture therapy. Appl Radiat Isot. 2025;218:111648. DOI:10.1016/j.apradiso.2024.111648.
■ 2014-2024
Tong Y, Imamichi S, Chen L, Nakamura S, Sato A, Sanada Y, Igaki H, Suzuki M, Itami J, Ishiai M, Masunaga S and Masutani M. Dynamic Expression Profiles of HMGB1 after BNCT and γ-Irradiation in Cancer Cells. J Oncology., 4(2), 1163, Dec 2024.
Kawasaki R, Oshige A, Yamana K, Hirano H, Nishimura K, Miura Y, Yorioka R, Sanada Y, Bando K, Tabata A, Yasuhara K, Miyazaki Y, Shinoda W, Nishimura T, Azuma H, Takata T, Sakurai Y, Tanaka H, Suzuki M, Nagasaki T and Ikeda A. HER-2-Targeted Boron Neutron Capture Therapy with Carborane-integrated Immunoliposomes Prepared via an Exchanging Reaction. Chemistry, 29(72), e202302486, DOI: 10.1002/chem.202302486. , Dec 2023.
Kawasaki R, Hirano H, Yamana K, Oshige A, Nishimura K, Kono N, Sanada Y, Bando K, Tabata A, Yasukawa N, Azuma H, Takata T, Sakurai Y, Tanaka H, Suzuki M, Tarutani N, Katagiri K, Nagasaki T and Ikeda A. Phospholipid-Coated Boronic Oxide Nanoparticles as Boron Agents for Boron Neutron Capture Therapy. Chembiochem, 24(15), e202300186, DOI: 10.1002/cbic.202300186. , Aug 2023.
Yamana K, Kawasaki R, Kondo K, Hirano H, Kawamura S, Sanada Y, Bando K, Tabata A, Azuma H, Takata T, Sakurai Y, Tanaka H, Kodama T, Kawamoto S, Nagasaki T and Ikeda A. HER-2-targeted boron neutron capture therapy using an antibody-conjugated boron nitride nanotube/β-1,3-glucan complex. Nanoscale Adv, 5(15), 3857-3861, DOI: 10.1039/d3na00028a. eCollection 2023 Jul 25., Jun 2023.
Perico D, Tong Y, Chen L, Imamichi S, Sanada Y, Ishiai M, Suzuki M, Masutani M and Mauri P. Proteomic Characterization of SAS Cell-Derived Extracellular Vesicles in Relation to Both BPA and Neutron Irradiation Doses. Cells, 12(12), 1562, DOI: 10.3390/cells12121562., Jun 2023.
Kawasaki R, Hirano H, Yamana K, Isozaki H, Kawamura S, Sanada Y, Bando K, Tabata A, Yoshikawa K, Azuma H, Takata T, Tanaka H, Sakurai Y, Suzuki M, Tarutani N, Katagiri K, Sawada S, Sasaki Y, Akiyoshi K, Nagasaki T and Ikeda A. Carborane bearing pullulan nanogel-boron oxide nanoparticle hybrid for boron neutron capture therapy. Nanomedicine, 49, 102659, DOI: 10.1016/j.nano.2023.102659. , Apr 2023.
Perico D, Di D, Imamichi S, Sanada Y, Masutani M and Luigi P. Systems Biology Approach to Investigate Biomarkers, Boron-10 Carriers, and Mechanisms Useful for Improving Boron Neutron Capture Therapy. Cancer Biother Radiopharm, 38(3), 152-159, DOI: 10.1089/cbr.2022.0053. , Apr 2023.
Masunaga S, Sanada Y, Takata T, Tanaka H, Sakurai Y, Suzuki M, Kirihata M and Ono K. The impact of TP53 status of tumor cells including the type and the concentration of administered 10B delivery agents on compound biological effectiveness in boron neutron capture therapy. J Radiat Res, 64(2), 399-411, DOI: 10.1093/jrr/rrad001., Mar 2023.
Watanabe T, Sanada Y, Hattori Y and Suzuki M. Correlation between the expression of LAT1 in cancer cells and the potential efficacy of boron neutron capture therapy. J Radiat Res, 64(1), 91-98, DOI: 10.1093/jrr/rrac077., Jan 2023.
Imamichi S, Chen L, Ito T, Tong Y, Onodera T, Sasaki Y, Nakamura S, Mauri P, Sanada Y, Igaki H, Murakami Y, Suzuki M, Itami J, Masunaga S and Masutani M. Extracellular Release of HMGB1 as an Early Potential Biomarker for the Therapeutic Response in a Xenograft Model of Boron Neutron Capture Therapy. Biology (Basel), 11(3), 420, DOI: 10.3390/biology11030420., Mar 2022.
Yamana K, Kawasaki R, Sanada Y, Tabata A, Bando K, Yoshikawa K, Azuma H, Sakurai Y, Masunaga S, Suzuki M, Sugikawa K, Nagasaki T and Ikeda A. Tumor-targeting hyaluronic acid/fluorescent carborane complex for boron neutron capture therapy. Biochem Biophys Res Commun, 559, 210-216, DOI: 10.1016/j.bbrc.2021.04.037. , Jun 2021.
Sanada Y, Takata T, Tanaka H, Sakurai Y, Watanabe T, Suzuki M and Masunaga S. HIF-1α affects sensitivity of murine squamous cell carcinoma to boron neutron capture therapy with BPA. Int J Radiat Biol, 97(10), 1441-1449, DOI: 10.1080/09553002.2021.1956004. , 2021.
Masunaga S, Sakurai Y, Tanaka H, Takata T, Suzuki M, Sanada Y, Tano K, Maruhashi A and Ono K. Usefulness of combination with both continuous administration of hypoxic cytotoxin and mild temperature hyperthermia in boron neutron capture therapy in terms of local tumor response and lung metastatic potential. Int. J. Radiat. Biol., 95(12), 1708-1717, DOI: 10.1080/09553002.2019.1666214, Dec 2019.
Masunaga S, Tano K, Sanada Y, Suzuki M, Takahashi A, Ohnishi K and Ono K. Effects of p53 status of tumor cells and combined treatment with mild hyperthermia, wortmannin or caffeine on recovery from radiation-induced damage. World J. Oncol., 10(3), 132-141, DOI: 10.14740/wjon1203, June 2019.
Sato T, Masunaga S, Kumada H and Hamada N. Depth Distributions of RBE-Weighted Dose and Photon-Isoeffective Dose for Boron Neutron Capture Therapy. Radiat. Prot. Dosim., 183(1-2), 247-250, DOI: 10.1093/rpd/ncy235, May 2019.
Masunaga S, Sakurai Y, Tanaka H, Takata T, Suzuki M, Sanada Y, Tano K, Maruhashi A and Ono K. Effect of a change in reactor power on response of murine solid tumors in vivo, referring to impact on quiescent tumor cell population. Int. J. Radiat. Biol., 95(5), 635-645, DOI: 10.1080/09553002.2019.1558300, May 2019.
Isono A, Tsuji M, Sanada Y, Matsushita A, Masunaga S, Hirayama T and Nagasawa H. Design, synthesis, and evaluation of lipopeptide conjugates of mercaptoundecahydrododecaborate for boron neutron capture therapy. Chem Med Chem, 2019(14), 823-832, DOI: 10.1002/cmdc.201800793, Apr 2019.
Tanaka H, Takata T, Ishi Y, Uesugi T, Kuriyama Y, Watanabe T, Sakurai Y, Kawabata S, Masunaga S and Suzuki M. Development of proton beam irradiation system for small animals using FFAG accelerator. Nucl. Instrum. Methods Phys. Res. A, 922, 230-234, DOI: 10.1016/j.nima.2018.12.081, Apr 2019.
Kanemitsu T, Kawabata S, Fukumura M, Futamura G, Hiramatsu R, Nonoguchi N, Nakagawa F, Takata T, Tanaka H, Suzuki M, Masunaga S, Ono K, Miyatake S, Nakamura H and Kuroiwa T. Folate receptor-targeted novel boron compound for boron neutron capture therapy on F98 glioma-bearing rats. Radiat. Environ. Biophys., 58(1), 59-67, DOI: 10.1007/s00411-018-0765-2, Mar 2019.
Ono K, Tanaka H, Tamari Y, Watanabe T, Suzuki M and Masunaga S. Proposal for determining absolute biological effectiveness of boron neutron capture therapy—the effect of 10B(n,α)7Li dose can be predicted from the nucleocytoplasmic ratio or the cell size. J. Radiat. Res., 60(1), 29–36, DOI: 10.1093/jrr/rry080, Jan 2019.
Masunaga S, Kobayashi J, Tano K, Sanada Y, Suzuki M and Ono K. The Effect of p53 Status on Radio-Sensitivity of Quiescent Tumor Cell Population Irradiated With γ-Rays at Various Dose Rates. J. Clin. Med. Res., J. Dermatol.,10(11), 815-821, DOI: 10.14740/jocmr3610w, Nov 2018.
Sanada Y, Sasanuma H, Takeda S, Tano K and Masunaga S. Disruption of Hif-1α enhances cytotoxic effects of metformin in murine squamous cell carcinoma. Int. J. Rad. Biol., 94(1), 88-96, DOI: 10.1080/09553002.2018.1409443, Jan 2018.
Masunaga S, Tano K, Sanada Y, Sakurai Y, Tanaka H, Suzuki M, Kondo N, Watanabe T, Takata T, Maruhashi A and Ono K. Effect of Tirapazamine, Metformin or Mild Hyperthermia on Recovery from Radiation-Induced Damage in Pimonidazole-Unlabeled Quiescent Tumor Cells. World J. Oncol., 8(5), 137-146, DOI: 10.14740/wjon1058w, Oct 2017.
Watanabe T, Hattori Y, Ohta Y, Ishimura M, Nakagawa Y, Sanada Y, Tanaka H, Fukutani S, Masunaga S, Hiraoka M, Ono K, Suzuki M and Kirihata M. Comparison of the pharmacokinetics between L-BPA and L-FBPA using the same administration dose and protocol: a validation study for the theranostic approach using [18F]-L-FBPA positron emission tomography in boron neutron capture therapy. BMC Cancer, 16:859, DOI: 10.1186/s12885-016-2913-x, Nov 2016.
Masunaga S, Tatebe H, Nishimura Y, Tano K, Sanada Y, Moriwaki T, Sakurai Y, Tanaka H, Suzuki M, Kondo N, Maruhashi A and Ono K. Effect of oxygen pressure during incubation with a 10B-carrier on 10B uptake capacity of cultured p53 wild-type and mutated tumor cells: dependency on p53 status of tumor cells and types of 10B-carriers. Int. J. Rad. Biol., 92(4), 187-194, Feb 2016.
Masunaga S, Uzawa A, Hirayama R, Matsumoto Y, Sakurai Y, Tanaka H, Tano K, Sanada Y, Suzuki M, Maruhashi A and Ono K. The effect of p53 status of tumor cells on radiosensitivity of irradiated tumors with carbon-ion beams compared with γ-rays or reactor neutron beams. World J. Oncol., 6(4), 398-409, Aug 2015.
Masunaga S, Sanada Y, Moriwaki T, Tano K, Sakurai Y, Tanaka H, SuzukiM, Kondo N, Narabayashi M, Watanabe T, Nakagawa Y, Maruhashi A and Ono K. Significance of Fractionated Administration of Thalidomide Combined With γ-Ray Irradiation in Terms of Local Tumor Response and Lung Metastasis. World J. Oncol., 5(4), 155-165, Aug 2014.
Sanada Y, Asai S, Ikemoto A, Moriwaki T, Nakamura N, Miyaji M and Zhang-Akiyama QM. Oxidation resistance 1 is essential for protection against oxidative stress and participates in the regulation of aging in Caenorhabditis elegans. Free Radic. Res., 48(8), 919-928, Aug 2014.
Sanada Y and Zhang-Akiyama QM. An increase of oxidized nucleotides activates DNA damage checkpoint pathway that regulates post-embryonic development in Caenorhabditis elegans. Mutagenesis, 29(2), 107-114, Feb 2014.
